Janus Henderson Group PLC Buys 876,431 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)

Janus Henderson Group PLC grew its stake in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 15.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,443,286 shares of the company's stock after purchasing an additional 876,431 shares during the period. Janus Henderson Group PLC owned approximately 10.10% of Larimar Therapeutics worth $24,936,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. BNP Paribas Financial Markets purchased a new stake in Larimar Therapeutics in the fourth quarter worth about $25,000. Algert Global LLC bought a new position in shares of Larimar Therapeutics in the 4th quarter worth approximately $47,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Larimar Therapeutics in the 4th quarter valued at approximately $52,000. Graham Capital Management L.P. purchased a new position in shares of Larimar Therapeutics in the 4th quarter valued at approximately $54,000. Finally, Aquatic Capital Management LLC bought a new stake in shares of Larimar Therapeutics during the fourth quarter valued at approximately $70,000. Institutional investors own 91.92% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Truist Financial initiated coverage on Larimar Therapeutics in a report on Wednesday, January 29th. They issued a "buy" rating and a $18.00 price objective for the company. HC Wainwright lifted their price target on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the company a "buy" rating in a research report on Tuesday, March 25th. Guggenheim restated a "buy" rating and issued a $26.00 price objective on shares of Larimar Therapeutics in a report on Tuesday, March 25th. Robert W. Baird decreased their target price on shares of Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating for the company in a research note on Tuesday, March 25th. Finally, Citigroup reissued a "buy" rating on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $19.63.

Larimar Therapeutics Trading Down 5.6%

NASDAQ:LRMR traded down $0.12 on Wednesday, reaching $1.95. 338,120 shares of the stock traded hands, compared to its average volume of 775,786. The company has a market capitalization of $124.53 million, a price-to-earnings ratio of -1.70 and a beta of 0.93. Larimar Therapeutics, Inc. has a 12 month low of $1.61 and a 12 month high of $11.20. The company's fifty day simple moving average is $2.17 and its 200 day simple moving average is $3.75.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04). Equities analysts anticipate that Larimar Therapeutics, Inc. will post -1.15 EPS for the current fiscal year.

Larimar Therapeutics Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.